<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134069</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00110</org_study_id>
    <secondary_id>07-0571</secondary_id>
    <secondary_id>R21CA117125</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <nct_id>NCT00134069</nct_id>
  </id_info>
  <brief_title>Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase I/II Clinical, Pharmacological, and Biological Study of BAY 43-9006 in Combination With Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of sorafenib when given&#xD;
      together with cetuximab and irinotecan and to see how well they work in treating patients&#xD;
      with advanced or metastatic colorectal cancer. Sorafenib may stop the growth of tumor cells&#xD;
      by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as&#xD;
      cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to&#xD;
      grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances&#xD;
      to them. Sorafenib and cetuximab may also stop tumor growth by blocking blood flow to the&#xD;
      tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to kill tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving sorafenib&#xD;
      together with cetuximab and irinotecan may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxicity spectrum and dose-limiting toxic effects of sorafenib when combined&#xD;
      with cetuximab and irinotecan in patients with advanced or metastatic colorectal cancer.&#xD;
&#xD;
      II. Determine the recommended phase II dose of sorafenib when combined with cetuximab and&#xD;
      irinotecan in these patients.&#xD;
&#xD;
      III. Correlate the clinical activity of this regimen, in terms of radiologic and positron&#xD;
      emission tomography (PET) response, with baseline extracellular signal-regulated kinase (ERK)&#xD;
      expression as well as Kirsten rat sarcoma (KRAS), BRAF, and other genetic properties of&#xD;
      tumors in these patients.&#xD;
&#xD;
      IV. Determine the pharmacokinetics of this regimen in these patients. V. Correlate the&#xD;
      pharmacodynamic effects of this regimen with baseline ERK expression as well as KRAS, BRAF,&#xD;
      and other genetic properties of tumors in these patients.&#xD;
&#xD;
      VI. Correlate the pharmacodynamic effects of this regimen on mitogen-activated protein kinase&#xD;
      (MAPK) status in peripheral blood mononuclear cells and on normal skin and oral mucosa with&#xD;
      clinical parameters in these patients.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study of sorafenib followed by a multicenter phase&#xD;
      II study.&#xD;
&#xD;
      PHASE I:&#xD;
&#xD;
      COURSE 1 (56 days): Patients receive oral sorafenib once or twice daily on days 1-56,&#xD;
      cetuximab IV over 1-2 hours on days 1, 8,15, 22, 29, 36, 43, and 50, and irinotecan IV over&#xD;
      90 minutes on days 15, 22, 29, and 36.&#xD;
&#xD;
      COURSE 2 AND ALL SUBSEQUENT COURSES (42 days): Patients receive oral sorafenib once or twice&#xD;
      daily on days 1-42, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36, and&#xD;
      irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 42 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of sorafenib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.&#xD;
&#xD;
      PHASE II: Patients receive sorafenib at the MTD determined in phase I, cetuximab, and&#xD;
      irinotecan as in phase I.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days.&#xD;
&#xD;
      *NOTE: This trial was intended to be Phase I/II, but the trial never continued to the Phase&#xD;
      II portion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity spectrum and dose-limiting toxicities of sorafenib in combination with cetuximab and irinotecan as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v 3.0</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose for phase II evaluation of the combination of sorafenib, cetuximab and irinotecan</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical activity of the combination of sorafenib, cetuximab and irinotecan in terms of radiological response</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of sorafenib, cetuximab, and irinotecan when given in combination or when given in combination with cetuximab alone and with cetuximab and irinotecan</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics of the combination of irinotecan when given in combination with sorafenib and cetuximab in tumor tissues</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage III Colon Cancer</condition>
  <condition>Stage III Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib, irinotecan, cetuximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 8 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 3-6. Patients will then receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 6 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 1-4. Treatment may repeat every 6 weeks for as long as benefit is shown.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (sorafenib, irinotecan, cetuximab)</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (sorafenib, irinotecan, cetuximab)</arm_group_label>
    <other_name>C225</other_name>
    <other_name>C225 monoclonal antibody</other_name>
    <other_name>IMC-C225</other_name>
    <other_name>MOAB C225</other_name>
    <other_name>monoclonal antibody C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (sorafenib, irinotecan, cetuximab)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal cancer (advanced or metastatic&#xD;
             disease not amenable to potential curative resection)&#xD;
&#xD;
          -  Archival tumor (blocks and/or slides) must be available for patients who decline tumor&#xD;
             biopsies&#xD;
&#xD;
          -  Tumor must be amenable to sequential biopsies for patients willing to undergo tumor&#xD;
             biopsy&#xD;
&#xD;
          -  Must have evidence of disease progression after first-line chemotherapy for advanced&#xD;
             disease&#xD;
&#xD;
          -  Previously irradiated lesions are not considered measurable disease&#xD;
&#xD;
          -  Measurable disease, defined as &gt;= 1 unidimensionally measurable target lesion &gt;= 20 mm&#xD;
             by conventional techniques OR &gt;= 10 mm by spiral CT scan&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2 OR Karnofsky 60-100%&#xD;
&#xD;
          -  Life expectancy of more than 12 weeks&#xD;
&#xD;
          -  white blood cell count (WBC) &gt;= 3,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  No hypertension&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Able to swallow oral medication&#xD;
&#xD;
          -  Willing to undergo 2 sequential tumor and skin biopsies&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to study drugs&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No prior cetuximab&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF), sargramostim (GM-CSF) or epoetin alfa&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior sorafenib&#xD;
&#xD;
          -  No other prior therapy targeted against MAPK&#xD;
&#xD;
          -  More than 14 days since prior and no concurrent administration of the following&#xD;
             cytochrome P450 3A4 (CYP3A4) inducers:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
          -  More than 7 days since prior and no concurrent administration of the following CYP3A4&#xD;
             inhibitors:&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Lopinavir in combination with ritonavir&#xD;
&#xD;
               -  Fosamprenavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Atazanavir&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Nefazodone&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Absolute neutrophil count &gt;=1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No evidence of bleeding diathesis&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 times upper&#xD;
             limit of normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wells Messersmith</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado at Denver Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado at Denver Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2005</study_first_posted>
  <last_update_submitted>April 15, 2014</last_update_submitted>
  <last_update_submitted_qc>April 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

